These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27927042)

  • 81. AMPed-up adolescents: The role of age in the abuse of amphetamines and its consequences on cognition and prefrontal cortex development.
    Westbrook SR; Carrica LK; Banks A; Gulley JM
    Pharmacol Biochem Behav; 2020 Nov; 198():173016. PubMed ID: 32828971
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A review of treatment options for co-occurring methamphetamine use disorders and depression.
    Hellem TL; Lundberg KJ; Renshaw PF
    J Addict Nurs; 2015; 26(1):14-23; quiz E1. PubMed ID: 25761159
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.
    Verrico CD; Haile CN; Newton TF; Kosten TR; De La Garza R
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1549-68. PubMed ID: 24033127
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence.
    Chen H; Wu J; Zhang J; Hashimoto K
    Curr Drug Abuse Rev; 2010 Dec; 3(4):222-38. PubMed ID: 21208168
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmacological approaches to methamphetamine dependence: a focused review.
    Karila L; Weinstein A; Aubin HJ; Benyamina A; Reynaud M; Batki SL
    Br J Clin Pharmacol; 2010 Jun; 69(6):578-92. PubMed ID: 20565449
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Gaps in the ice: Methamphetamine in Australia; its history, treatment, and ramifications for users and their families.
    Gordon DG; de Jong G
    Int J Ment Health Nurs; 2018 Dec; 27(6):1861-1868. PubMed ID: 29869828
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Future pharmacological treatments for substance use disorders.
    Forray A; Sofuoglu M
    Br J Clin Pharmacol; 2014 Feb; 77(2):382-400. PubMed ID: 23039267
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Access to Inpatient Rehabilitation of Methamphetamine Addiction - Barriers and Potential for Improvement from the Experts' Perspective].
    Hoffmann L; Schumann N; Richter M
    Rehabilitation (Stuttg); 2018 Dec; 57(6):364-371. PubMed ID: 29183100
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Immunotherapy for treating methamphetamine, heroin and cocaine use disorders.
    Xiaoshan T; Junjie Y; Wenqing W; Yunong Z; Jiaping L; Shanshan L; Kutty Selva N; Kui C
    Drug Discov Today; 2020 Mar; 25(3):610-619. PubMed ID: 31419495
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Methamphetamine-Related Disorders.
    Gouzoulis-Mayfrank E; Härtel-Petri R; Hamdorf W; Havemann-Reinecke U; Mühlig S; Wodarz N
    Dtsch Arztebl Int; 2017 Jun; 114(26):455-461. PubMed ID: 28705298
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review.
    Paulus MP; Stewart JL
    JAMA Psychiatry; 2020 Sep; 77(9):959-966. PubMed ID: 32267484
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Current status and future prospects for the development of substance abuse vaccines.
    Heekin RD; Shorter D; Kosten TR
    Expert Rev Vaccines; 2017 Nov; 16(11):1067-1077. PubMed ID: 28918668
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Partial MHC/neuroantigen peptide constructs: a potential neuroimmune-based treatment for methamphetamine addiction.
    Loftis JM; Wilhelm CJ; Vandenbark AA; Huckans M
    PLoS One; 2013; 8(2):e56306. PubMed ID: 23460798
    [TBL] [Abstract][Full Text] [Related]  

  • 94. What matters in measuring methamphetamine-related cognitive impairments: 'abnormality detection' versus 'everyday import'?
    Payer DE; Dean AC; Boileau I
    Neuropsychopharmacology; 2012 Apr; 37(5):1081-2. PubMed ID: 22419225
    [No Abstract]   [Full Text] [Related]  

  • 95. Commentary on Heinzerling et al. (2014): a growing methamphetamine dependence therapeutics graveyard.
    Carson DS; Taylor ER
    Addiction; 2014 Nov; 109(11):1887-8. PubMed ID: 25297959
    [No Abstract]   [Full Text] [Related]  

  • 96. Neuroimmune mechanisms of psychostimulant and opioid use disorders.
    Hofford RS; Russo SJ; Kiraly DD
    Eur J Neurosci; 2019 Aug; 50(3):2562-2573. PubMed ID: 30179286
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Methamphetamine addiction: do biological rhythms matter, and could they play a role in treatment?
    Ogeil RP; Arunogiri S; Grigg J
    Sleep; 2021 Jul; 44(7):. PubMed ID: 33693834
    [No Abstract]   [Full Text] [Related]  

  • 98. Current Understanding of Methamphetamine-Associated Metabolic Changes Revealed by the Metabolomics Approach.
    Kim M; Jang WJ; Shakya R; Choi B; Jeong CH; Lee S
    Metabolites; 2019 Sep; 9(10):. PubMed ID: 31547093
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cannabidiol as a pharmacotherapy tool for attenuating methamphetamine effects.
    Pastor V
    Am J Drug Alcohol Abuse; 2022 Sep; 48(5):507-508. PubMed ID: 35867421
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.